FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - February 11, 2026 207 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with... August 10, 2022 Cancer Patient’s Appetite Increases And His Blood Pressure Lowers After A... September 24, 2019 Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell... July 15, 2025 Tackling under-representation of Black data scientists in cancer research November 7, 2022 Load more HOT NEWS Molecular Burglary: Cancer Cells Hijack Energy from Immune Cells Phytochemicals and Antioxidants Savolitinib Shows Promise in Pulmonary Sarcomatoid Carcinoma and Other METex14-positive NSCLC... For Children with Neuroblastoma, Trial Results Highlight Continued Evolution of Treatment
